Clinical Trial Update: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial from BioNTech assessing safety and immune responses of two investigational RNA-based vaccines against tuberculosis in BCG-vaccinated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Investigational RNA-based Vaccine A
• Investigational RNA-based Vaccine B

Snippet

Sponsor: BioNTech SE | Conditions: Tuberculosis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING